Search

Your search keyword '"Balbir-Gurman A"' showing total 817 results

Search Constraints

Start Over You searched for: Author "Balbir-Gurman A" Remove constraint Author: "Balbir-Gurman A"
817 results on '"Balbir-Gurman A"'

Search Results

1. High Body Mass Index is Associated with Shorter Retention of Tumor Necrosis Factor-Alpha Blocker Treatment in Rheumatoid Arthritis

2. Contributors

4. Untangling the relationship between smoking and systemic sclerosis: an analysis of the EUSTAR cohort

6. Does the Impact of COVID‐19 on Patients With Systemic Sclerosis Change Over Time?

7. Cohort Enrichment Strategies for Progressive Interstitial Lung Disease in Systemic Sclerosis From European Scleroderma Trials and Research

8. The Role of CCL24 in Systemic Sclerosis

10. POS0235 NEW ONSET OF INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS: CLINICAL COURSE AND OUTCOMES FROM A EUSTAR DATABASE ANALYSIS

11. POS0211 PAH TREATMENT AT TIME OF DIAGNOSIS IS ASSOCIATED WITH IMPROVED SURVIVAL REGARDLESS OF HEMODYNAMIC THRESHOLDS AND RISK STRATIFICATION - A EUSTAR ANALYSIS

12. POS0230 CHARACTERISTICS AND DISEASE COURSE OF SSc-ILD PATIENTS WITH GASTROESOPHAGEAL REFLUX – AN ANALYSIS OF THE EUSTAR COHORT

15. Untangling the relationship between smoking and systemic sclerosis: an analysis of the EUSTAR cohort

16. Stratification in systemic sclerosis according to autoantibody status versus skin involvement: a study of the prospective EUSTAR cohort

17. Environmental and societal factors associated with COVID-19-related death in people with rheumatic disease: an observational study

18. A deep look into the storm: Israeli multi-center experience of coronavirus disease 2019 (COVID-19) in patients with autoimmune inflammatory rheumatic diseases before and after vaccinations

20. An unexpected diagnosis of a 57-year-old women with migratory pulmonary infiltrates

21. Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study

22. Does the impact of COVID-19 on patients with systemic sclerosis change over time?

24. Cohort Enrichment Strategies for Progressive Interstitial Lung Disease in Systemic Sclerosis From European Scleroderma Trials and Research

27. Comparison of risk stratification models for prediction of mortality in SSc-PAH in EUSTAR

28. Does the impact of COVID‐19 on patients with systemic sclerosis change over time?

29. Predictors of Immunogenic Response to the BNT162b2 mRNA COVID-19 Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases Treated with Rituximab

30. Longitudinally Extensive Transverse Myelitis in a Lupus–Neuromyelitis Optica Overlap

31. Use of platelet inhibitors for digital ulcers related to systemic sclerosis: EUSTAR study on derivation and validation of the DU-VASC model

32. OP0238 IMMUNOSUPPRESSION WITH TARGETED DMARDS REDUCES MORBIDITY AND MORTALITY IN PRE-CAPILLARY PULMONARY HYPERTENSION ASSOCIATED WITH SYSTEMIC SCLEROSIS: A EUSTAR ANALYSIS

33. OP0234 2023 UPDATE OF EULAR RECOMMENDATIONS FOR THE TREATMENT OF SYSTEMIC SCLEROSIS

34. POS1263 SMOKING INFLUENCE ON AUTOANTIBODY PROFILE AND DISEASE PROGRESSION IN SYSTEMIC SCLEROSIS: AN EUSTAR DATABASE ANALYSIS

35. POS0121 COMPARISON OF FOUR RISK STRATIFICATION MODELS FOR PREDICTION OF MORTALITY IN SSc-PAH IN THE EUSTAR COHORT

37. POS0544 THE CONTRIBUTION OF THE 3RD AND 4TH BOOSTER BNT162B2 MRNA VACCINES TO PREVENT SEVERE COVID-19 AMONG AUTOIMMUNE INFLAMMATORY RHEUMATOID DISEASES (AIRD) PATIENTS DURING THE OMICRON OUTBREAKS

40. Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from the EUSTAR cohort

41. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial

44. Systemic sclerosis and primary biliary cholangitis: Longitudinal data to determine the outcomes

45. A deep look into the storm: Israeli multi-center experience of coronavirus disease 2019 (COVID-19) in patients with autoimmune inflammatory rheumatic diseases before and after vaccinations

46. Environmental and societal factors associated with COVID-19-related death in people with rheumatic disease: an observational study

47. Stratification in systemic sclerosis according to autoantibody status versus skin involvement: a study of the prospective EUSTAR cohort

48. An international SUrvey on non-iNvaSive tecHniques to assess the mIcrocirculation in patients with RayNaud’s phEnomenon (SUNSHINE survey)

49. Real-world effectiveness of tofacitinib in patients with rheumatoid arthritis: a prospective observational study

50. Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from EUSTAR cohort

Catalog

Books, media, physical & digital resources